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Abstract
Background: Simpson-Angus Scale (SAS) is an established instrument for neuroleptic-induced
parkinsonism (NIP), but its statistical properties have been studied insufficiently. Some
shortcomings concerning its content have been suggested as well. According to a recent report,
the widely used SAS mean score cut-off value 0.3 of for NIP detection may be too low. Our aim
was to evaluate SAS against DSM-IV diagnostic criteria for NIP and objective motor assessment
(actometry).
Methods: Ninety-nine chronic institutionalised schizophrenia patients were evaluated during the
same interview by standardised actometric recording and SAS. The diagnosis of NIP was based on
DSM-IV criteria. Internal consistency measured by Cronbach's α , convergence to actometry and
the capacity for NIP case detection were assessed.
Results: Cronbach's α  for the scale was 0.79. SAS discriminated between DSM-IV NIP and non-
NIP patients. The actometric findings did not correlate with SAS. ROC-analysis yielded a good case
detection power for SAS mean score. The optimal threshold value of SAS mean score was between
0.65 and 0.95, i.e. clearly higher than previously suggested threshold value.
Conclusion:  We conclude that SAS seems a reliable and valid instrument. The previously
commonly used cut-off mean score of 0.3 has been too low resulting in low specificity, and we
suggest a new cut-off value of 0.65, whereby specificity could be doubled without loosing sensitivity.
Background
Reported prevalences for neuroleptic-induced parkinson-
ism (NIP) in schizophrenia patients are usually in the
range 19% to 36% [1-5]. As NIP can severely impair activ-
ities of daily life, and it can be treated or at least alleviated,
its diagnosis and assessment are an important focus in
clinical practice. A reliable diagnosis of NIP is a demand-
ing task [6]. NIP may be missed due to overlap with neg-
ative and depressive symptoms in treated schizophrenia
patients [7]. Diagnostic and Statistical Manual, fourth edi-
tion, (DSM-IV) [8] criteria for NIP consist of parkinsonian
tremor, muscular rigidity or akinesia, developing within a
few weeks of starting or raising the dose of a neuroleptic
medication (or after reducing a medication used to treat
extrapyramidal symptoms). Like other motor adverse
effects of antipsychotic drugs, the NIP is usually assessed
Published: 17 March 2005
BMC Neurology 2005, 5:5 doi:10.1186/1471-2377-5-5
Received: 01 November 2004
Accepted: 17 March 2005
This article is available from: http://www.biomedcentral.com/1471-2377/5/5
© 2005 Janno et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Neurology 2005, 5:5 http://www.biomedcentral.com/1471-2377/5/5
Page 2 of 6
(page number not for citation purposes)
by clinical observation or by rating scales, which are based
on clinician's judgement. Movement disorders such as
NIP, however, can be measured objectively by recording
motor activity [9-12].
Simpson-Angus Scale (SAS) is a 10-item rating scale that
has been used widely for assessment of NIP in both clini-
cal practice and research settings [13]. It consists of one
item measuring gait (hypokinesia), six items measuring
rigidity and three items measuring glabella tap, tremor
and salivation, respectively. It is an established rating
scale, but some shortcomings have been suggested: the
rigidity items may be given too much emphasis, the statis-
tical properties have been studied insufficiently, and the
instructions as well as the definitions are somewhat
unclear [14]. Several items of the scale have failed to show
appropriate interrater reliability or insufficient variability
across elderly patients [15], and a modified version has
been used to determine the prevalence of spontaneous
parkinsonism and the incidence of NIP in this population
[16].
According to our recent study [17] there was a discrepancy
between SAS and DSM-IV based NIP prevalence estimates.
We suggested that the commonly used cut-off point of 0.3
mean SAS score was too low in a naturalistic clinical pop-
ulation [17].
Accelerometric methods have been developed to identify
and monitor motor NIP symptoms, such as tremor
[18,19] and hypokinesia [20]. A standardized actometric
method has been developed for the assessment of neu-
roleptic-induced akathisia (NIA) [21]. This method dis-
criminated pure NIA patients from healthy controls and
from themselves in remission phase with no overlap [21].
In the current clinical population (including patients with
NIP and tardive dyskinesia in addition to NIA), however,
the method evidenced less diagnostic power [22]. NIP
symptoms may have confounded these actometric
findings.
The discrepancy between SAS and DSM-IV based NIP
prevalence estimates as well as other above mentioned
shortcomings suggest that SAS needs an evaluation as a
method to assess NIP severity and to find reliably NIP
cases.
Our aims were to check the internal consistency of SAS,
improve the convergence between DSM IV and SAS based
NIP case finding, and to evaluate how well the scale meas-
ures objective motor symptoms verified by actometry.
Methods
We recruited 99 chronic schizophrenic institutionalized
adult patients from a state nursing home in central Esto-
nia [17]. Inclusion criteria were DSM-IV diagnosis of
schizophrenia or schizoaffective disorder, stable antipsy-
chotic medication (for at least one month), and age of
18–65 years. Diagnosis was made using a semi-structured
interview according to DSM-IV criteria for schizophrenia
by a psychiatrist (SJ) and medical records. Patients with
severe somatic illness or neurological illness were
excluded. Written informed consent was obtained from
the subjects and the study was approved by the Ethics
Review Committee on Human Research of the University
of Tartu. Data were collected from 29.10.2001 to
27.03.2002.
An experienced clinician (SJ) assessed all the subjects to
identify NIP cases in accordance with DSM-IV. The DSM-
IV diagnostic criteria for other neuroleptic-induced move-
ment disorders (NIMD) were also checked because of fre-
quent comorbidity and common aetiology. Clinical NIP
symptoms were assessed by SAS and the motor activity
during rest was measured by actometry. Each item of the
10-item SAS is rated on a 5-point scale (0–4), and the
mean score is obtained by adding the items and dividing
by 10 [13]. Neuroleptic-induced akathisia and tardive dys-
kinesia were rated by Barnes Akathisia Rating Scale
(BARS) [23] and Abnormal Involuntary Movement Scale
(AIMS) [24].
The actometric recording was performed during sitting in
a standardized clinical interview for 30 minutes, a method
described previously as measuring "controlled rest activ-
ity" [19,21]. Controlled rest activity is a parameter of
motor activity in a situation where sitting still is adequate
and expected, but not instructed or required. The actome-
ters (PAM3, Individual Monitoring Systems, Baltimore,
USA) were attached to the ankles of the subjects to meas-
ure lower limb motor activity. Actometers are wireless,
computerized movement detectors of match-box-size,
which do not influence normal moving of the patient.
Cronbach's α  was assessed to evaluate the internal consist-
ency of the scale. The correlations between the lower limb
activity (the mean of right and left ankle movement indi-
ces) and individual item scores and mean SAS scores were
analysed. Differences between the NIP and non-NIP, as
well as the NIMD and the non-NIMD groups in the SAS
mean score and lower limb activity were analysed. The
performance of SAS mean score and individual item
scores in case identification was evaluated by receiver
operating characteristics (ROC) analyses against DSM-IV
NIP diagnosis. Validity coefficients (specificity, sensitivity,
positive and negative predictive value [PPV and NPV,
respectively]) for different mean SAS score thresholds
were calculated. To explore the discriminatory power of
each single SAS item we performed ROC analyses for each
item separately. We also explored the effect on the validityBMC Neurology 2005, 5:5 http://www.biomedcentral.com/1471-2377/5/5
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coefficients of merging the six rigidity items of SAS into
one single item, to de-emphasise the influence of rigidity
on the mean SAS score. The Spearman test was used to
correlation analysis and the Mann-Whitney 2-tailed U-test
for the comparison between two groups because of the
non-normal distribution of the data. The software used in
analyses was SPSS 11.0. [25].
Results
Of the 99 participants, 45 (45.5%) were male and 54
(54.5%) female. The mean age was 49.7 (SD 9.5) years.
The mean continuous treatment in hospital or in nursing
home was 13.6 (SD 9.0) years. Seventy-nine (79.8%)
patients used conventional antipsychotics (70 on low-
dose, and 9 on high-dose neuroleptics) and 20 (20.2%)
used clozapine (one was receiving clozapine combined
with sulpiride). Low-dose antipsychotics in this study
were haloperidol, cyclopentixol, perphenazine and flu-
phenazine; high dose antipsychotics were chlorpro-
mazine, thioridazine, levomepromazine, chlorprotixen
and sulpiride. Sixteen (16.2%) patients were receiving
combinations of typical antipsychotics (either predomi-
nantly low-dose [N = 10] or predominantly high-dose [N
= 6] neuroleptic regimens), and 63 (63.6%) were receiv-
ing monotherapy (haloperidol: N = 29; zuclopenthixol: N
= 28; perphenazine, chlorpromazine, or thioridazine: N =
6). No new atypical antipsychotics were used. The mean
daily chlorpromazine equivalent conditions. The preva-
lence of any NIMD according to DSM-IV was 61.6% in the
whole sample. Cronbach's α  for SAS was 0.79. dose [26]
was 328 (SD 221) mg. The prevalence of NIP according to
DSM-IV criteria was 23.2%. Fourteen patients, all from
non-NIP subgroup, used an anticholinergic drug (trihexy-
phenidyl). Only 10 of the 23 patients with NIP presented
as pure NIP without comorbidity of other motor disor-
ders. Among patients with NIP, 10 had comorbid aka-
thisia and 6 tardive dyskinesia; three of them had all three
The SAS mean score correlated significantly with age in
our population (r = 0.203, p = 0.044).
Convergence of SAS and actometry to DSM-IV NIP 
diagnosis
The SAS mean score for DSM-IV NIP patients (1.24, SD =
0.44) was significantly higher from that (0.56, SD = 0.33)
of non-NIP patients (U = -6.90, p = 0.000). The mean
scores of each single SAS item are presented in Table 1.
The mean scores of "glabella tap" and "salivation" items
for NIP patients were not significantly higher from that of
non-NIP patients. The SAS mean score for NIMD patients
was significantly higher from that of non-NIMD patients
(U=-5.77, p = 0.000).
Actometric data was missing for one male patient due to
non-co-operation. The median lower limb activity for NIP
patients was not significantly higher than that of non-NIP
patients (U = -0.46, p = 0.643). The median lower limb
activity for NIMD patients was significantly higher from
that of non-NIMD patients (U=-2.66, p = 0.008).
Convergence of SAS to actometry
The SAS mean score did not correlate significantly with
actometric lower limb activity either in the whole popula-
tion (r = 0.04, p = 0.717), in the NIP group (r = -0.29, p =
0.192), or in the pure NIP subgroup (r = -0.21, p = 0.587).
Even after a post-hoc analysis of co-variance in the whole
population, where the effect of akathisia (BARS global
score) and tardive dyskinesia (AIMS severity score) were
controlled for, no significant correlation between SAS
mean score and the lower limb activity could be found (r
= 0.07, p = 0.494).
The tremor item of the SAS correlated significantly with
the lower limb activity in the whole population (r = 0.25,
p = 0.013) but not in the NIP population (r = 0.26, p =
0.248) or in the pure NIP subgroup (r = 0.51, p = 0.160).
No correlation was evidenced between the hypokinesia
item of the SAS and lower limb activity in the whole pop-
ulation (r = -0.07, p = 0.513) either in NIP population (r
= -0.24, p = 0.290) or in pure NIP subgroup (r = -0.37, p
= 0.797).
No correlation was evidenced between the mean of rigid-
ity items of the SAS and lower limb activity in the whole
population (r = -0.12, p = 0.256) either in NIP population
(r = -0.37, p = 0.090) or in pure NIP subgroup (r = -0.30,
p = 0.426).
NIP case finding by SAS
ROC-curve for screening performance of SAS mean score
is presented in Fig 1. Area under the ROC-curve (AUC) for
SAS mean score was 0.92 (CI = 0.87–0.97). AUC of the
Table 1: Mean scores of Simpson-Angus Scale (SAS) items in 
Neuroleptic-Induced Parkinsonism (NIP) group and non-NIP 
group.
SAS item NIP-group Non-NIP group
Gait 1.04 0.38
Arm dropping 1.43 0.59
Shoulder shaking 1.09 0.33
Elbow rigidity 1.83 0.47
Wrist rigidity 0.91 0.16
Leg pendulousness 0.91 0.28
Head dropping 1.48 0.66
Glabella tap 1.09 0.86
Tremor 1.78 1.14
Salivation 0.83 0.71
Mean of SAS items 1.24 0.56BMC Neurology 2005, 5:5 http://www.biomedcentral.com/1471-2377/5/5
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ROC curve for SAS elbow rigidity item was 0.93 (CI = 0.86
– 1.0). AUC for the other items was less than 0.82. AUC in
ROC analyses may range from of 0.5 (no case finding
power) to 1.0 (optimal case finding performance). The
validity coefficients of the SAS mean score are presented in
Table 2.
ROC-curve for screening performance of SAS mean with
single averaged rigidity item was clearly inferior to the
original SAS mean curve with AUC of 0.80 (CI = 0.70–
0.89).
The screening performances of the individual SAS items
for NIP case finding are shown at Table 3.
As SAS elbow rigidity item had case finding power similar
to SAS mean score, we calculated optimal cut-off for this
item. Cut-off threshold of 1.5, with sensitivity of 0.826
and specificity of 0.974, was superior to cut-off threshold
of 0.5 with sensitivity of 0.957 and specificity 0.553.
Discussion
Our study aimed to evaluate some of the characteristics of
the SAS and its utility for identifying and measuring NIP
in a naturalistic schizophrenia sample. The internal con-
sistency of SAS was satisfactory, which suggests sufficient
reliability for the scale. We compared the SAS with the
DSM-IV to assess its discriminant validity and evaluate it
in detecting NIP cases. The comparison with objective
movement assessment aimed to estimate the concurrent
validity of SAS in NIP severity measurement.
As expected, the SAS had discriminant validity for a clini-
cal diagnosis of NIMD. SAS mean score discriminated
NIMD patients well from those without NIMD, and more
specifically, also NIP patients from other patients. Actom-
etry discriminated NIMD patients from non-NIMD
patients, but did not identify DSM-IV NIP patients.
According to ROC analysis the SAS had good case finding
properties converging with the DSM IV NIP diagnosis. In
our population the commonly used threshold 0.3 was
inappropriate: according to our results the optimal cut-off
point should be between 0.65 – 0.95 depending on the
emphasis in the trade-off between sensitivity and specifi-
city. We suggest that the new cut-off value for screening
NIP could be 0.65, whereby specificity could be doubled
without loosing any sensitivity. To be useful for diagnostic
purposes a combination of high specificity and high pos-
itive predictive value (PPV) is reached at cut-off – 0.75
[27]. To answer to criticism about the overrepresentation
of rigidity items, we averaged the six items into one item.
This procedure worsened the NIP case detection capacity
of the SAS.
Using the single elbow rigidity item for case detection had
the same (or slightly better) case detection capacity as the
SAS mean score. This finding supports the use of elbow
rigidity testing when assessing parkinsonism in clinical
settings, as cut-off value 0.5 has good sensitivity and spe-
cificity for DSM-IV NIP.
We found that SAS mean score did not correlate with acto-
metric lower limb activity, and hypokinesia observed dur-
ing gait item of SAS did not correlate with actometric
motor activity during the 30-minute recording. There are
a few explanations for that:
First, actometry measures only the productive motor
dimension of the parkinsonian symptoms while SAS takes
into account also rigidity, gait, salivation and glabella tap,
with a clear emphasis on rigidity. Lack of correlation with
actometric findings in NIP subgroup indicates that tremor
may not be the core feature of NIP. This is also supported
by the small AUC for the tremor item of SAS.
Secondly, we used lower-limb actometry while the clinical
assessment by SAS and DSM-IV considered predomi-
nantly upper limbs. Parkinsonism may be more sympto-
matic in upper limbs, and the upper limb disturbances
may have influenced our SAS and DSM IV assessments
more than lower limb disturbances. Our findings indicate
that lower limb actometry is not suitable for diagnosing
NIP.
Receiver Operating Characteristic (ROC) curve for SAS  mean score against DSM-IV defined Neuroleptic-Induced  Parkinsonism (NIP) Figure 1
Receiver Operating Characteristic (ROC) curve for SAS 
mean score against DSM-IV defined Neuroleptic-Induced 
Parkinsonism (NIP).BMC Neurology 2005, 5:5 http://www.biomedcentral.com/1471-2377/5/5
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Thirdly, diurnal naturalistic actometry may have more
power in detecting hypokinesia.
Limitations
This study was limited to a few aspects of utility/validity
of the SAS: internal consistency, convergence to DSM-IV
NIP diagnosis and convergence to objectively measured
motor activity. Many aspects of the scale's reliability (e.g.
test-retest and inter-rater reliability) and validity (e.g. con-
struct) were not evaluated.
DSM-IV was used as a standard in this study, but there is
not much data available on the validity of NIP criteria of
the DSM-IV. A better golden standard in this study would
probably have been an expert-consensus diagnosis. Fur-
thermore, as there was only one rater for the scales, a
cross-scale contamination issue might have occurred.
It is known that with age the prevalence of spontaneous
NIMD rises. Our material did not allow a thorough
examination of the issue, but age correlated with SAS
mean score in our sample.
The measurement of motor activity here was purely quan-
titative; we did not assess the patterns of the disordered
movements.
Conclusion
As a conclusion, SAS seems be a reliable and a valid instru-
ment. It performs well and similarly to DSM-IV in NIP
case detection. The optimal SAS mean score cut-off value
in a naturalistic population of neuroleptic-treated schizo-
phrenia patients is higher than the commonly used 0.3.
We suggest that the new cut-off value for screening NIP
could be 0.65, whereby specificity could be doubled with-
out loosing sensitivity. Combining SAS rigidity items does
not seem to improve the performance of the scale.
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Table 2: Validity coefficients of the Simpson-Angus Scale (SAS) mean score at different cutoff values. The optimal cut-off point range 
is presented in bold text.
SAS mean 
cut-off
0.25 0.35 0.45 0.55 0.65 0.75 0.85 0.95 1.05 1.15
Sensitivity 1.0 1.0 1.0 1.0 1.0 0.96 0.87 0.78 0.70 0.52
Specificity 0.17 0.36 0.45 0.49 0.62 0.74 0.86 0.86 0.89 0.93
Positive 
Predictive 
Value
0.27 0.32 0.35 0.37 0.44 0.96 0.65 0.64 0.67 0.71
Negative 
Predictive 
Value
1 . 01 . 01 . 01 . 01.0 0.98 0.96 0.93 0.91 0.87
Table 3: Area under the ROC curve of Simpson-Angus Scale 
(SAS) parameters against DSM-IV diagnosis of Neuroleptic-
Induced Parkinsonism.
SAS item Area under 
the ROC 
curve
Gait 0.71
Arm dropping 0.79
Shoulder shaking 0.81
Elbow rigidity 0.93
Wrist rigidity 0.75
Leg pendulousness 0.73
Head dropping 0.75
Glabella tap 0.57
Tremor 0.66
Salivation 0.53
Mean of rigidity items 0.92
Mean of mean rigidity items and other SAS items 0.80
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